|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/6/2010 11:17:16 AM
FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC” OTCBB: GTCB.OB) announced today that it had completed its previously announced sale of approximately 61,100,000 shares of its common stock, par value $0.01 per share, to LFB Biotechnologies S.A.S., Les Ulis, France (“LFB”) in a private placement for $0.30 per share, for an aggregate purchase price of approximately $18.3 million. Following the private placement and the conversion of convertible preferred stock of GTC owned by LFB, LFB owned at least 90% of GTC’s outstanding common stock.
|
|
|
|
|
|
|
|
|
|
|